Reference
1. Sundström Rehal M, Tjäder I, Wernerman J. Nutritional needs for the critically ill in relation to inflammation. Current opinion in clinical nutrition and metabolic care. 2016;19(2):138-43.
2. McClave SA, Taylor BE, Martindale RG, Warren MM, Johnson DR, Braunschweig C, et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr. 2016;40(2):159-211.
3. Powers J, Samaan K. Malnutrition in the ICU patient population. Critical Care Nursing Clinics. 2014;26(2):227-42.
4. Koekkoek KW, van Zanten AR. Nutrition in the critically ill patient. Current Opinion in Anesthesiology. 2017;30(2):178-85.
5. McClave SA, Taylor BE, Martindale RG, Warren MM, Johnson DR, Braunschweig C, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (ASPEN). Journal of Parenteral and Enteral Nutrition. 2016;40(2):159-211.
6. Adeva‐Andany MM, Calvo‐Castro I, Fernández‐Fernández C, Donapetry‐García C, Pedre‐Piñeiro AM. Significance of l‐carnitine for human health. IUBMB life. 2017;69(8):578-94.
7. Pekala J, Patkowska-Sokola B, Bodkowski R, Jamroz D, Nowakowski P, Lochynski S, et al. L-carnitine–metabolic functions and meaning in humans life. Curr Drug Metab. 2011;12(7):667-78.
8. Uziel G, Garavaglia B, Di Donato S. Carnitine stimulation of pyruvate dehydrogenase complex (PDHC) in isolated human skeletal muscle mitochondria. Muscle Nerve. 1988;11(7):720-4.
9. Amat di San Filippo C, Taylor MR, Mestroni L, Botto LD, Longo N. Cardiomyopathy and carnitine deficiency. Mol Genet Metab. 2008;94(2):162-6.
10. Oami T, Oshima T, Hattori N, Teratani A, Honda S, Yoshida T, et al. l-carnitine in critically ill patients—a case series study. Renal Replacement Therapy. 2018;4(1):13.
11. Duranay M, Akay H, Yilmaz FM, Senes M, Tekeli N, Yucel D. Effects of L-carnitine infusions on inflammatory and nutritional markers in haemodialysis patients. Nephrol Dial Transplant. 2006;21(11):3211-4.
12. Dastan F, Talasaz AH, Mojtahedzadeh M, Karimi A, Salehiomran A, Bina P, et al. Randomized Trial of Carnitine for the Prevention of Perioperative Atrial Fibrillation. Semin Thorac Cardiovasc Surg. 2018;30(1):7-13.
13. Lee B-J, Lin J-S, Lin Y-C, Lin P-T. Antiinflammatory effects of L-carnitine supplementation (1000 mg/d) in coronary artery disease patients. Nutrition. 2015;31(3):475-9.
14. Lysiak W, Lilly K, DiLisa F, Toth P, Bieber L. Quantitation of the effect of L-carnitine on the levels of acid-soluble short-chain acyl-CoA and CoASH in rat heart and liver mitochondria. Journal of Biological Chemistry. 1988;263(3):1151-6.
15. Broderick TL, Quinney HA, Lopaschuk GD. Carnitine stimulation of glucose oxidation in the fatty acid perfused isolated working rat heart. Journal of Biological Chemistry. 1992;267(6):3758-63.
16. Gülcin İ. Antioxidant and antiradical activities of L-carnitine. Life sciences. 2006;78(8):803-11.
17. Binienda ZK, Ali SF. Neuroprotective role of L-carnitine in the 3-nitropropionic acid induced neurotoxicity. Toxicology letters. 2001;125(1-3):67-73.
18. Augustyniak A, Skrzydlewska E. The influence of L-carnitine suplementation on the antioxidative abilities of serum and the central nervous system of ethanol-induced rats. Metabolic brain disease. 2010;25(4):381-9.
19. Miguel-Carrasco JL, Monserrat MT, Mate A, Vázquez CM. Comparative effects of captopril and l-carnitine on blood pressure and antioxidant enzyme gene expression in the heart of spontaneously hypertensive rats. European journal of pharmacology. 2010;632(1-3):65-72.
20. Setia S, Sanyal SN. Nuclear Factor Kappa B: A Pro-Inflammatory, Transcription Factor− Mediated Signalling Pathway in Lung Carcinogenesis and Its Inhibition By Nonsteroidal Anti-Inflammatory Drugs. Journal of Environmental Pathology, Toxicology and Oncology. 2012;31(1).
21. Siomek A. NF-κB signaling pathway and free radical impact. Acta Biochimica Polonica. 2012;59(3).
22. Zambrano S, Blanca AJ, Ruiz-Armenta MV, Miguel-Carrasco JL, Arévalo M, Vázquez MJ, et al. L-Carnitine protects against arterial hypertension-related cardiac fibrosis through modulation of PPAR-γ expression. Biochemical Pharmacology. 2013;85(7):937-44.
23. Shakeri A, Tabibi H, Hedayati M. Effects of l‐carnitine supplement on serum inflammatory cytokines, C‐reactive protein, lipoprotein (a), and oxidative stress in hemodialysis patients with Lp (a) hyperlipoproteinemia. Hemodialysis international. 2010;14(4):498-504.
24. Savica V, Santoro D, Mazzaglia G, Ciolino F, Monardo P, Calvani M, et al. L-carnitine infusions may suppress serum C-reactive protein and improve nutritional status in maintenance hemodialysis patients. J Ren Nutr. 2005;15(2):225-30.
25. Volek JS, Judelson DA, Silvestre R, Yamamoto LM, Spiering BA, Hatfield DL, et al. Effects of carnitine supplementation on flow-mediated dilation and vascular inflammatory responses to a high-fat meal in healthy young adults. Am J Cardiol. 2008;102(10):1413-7.
26. Rafraf M, Karimi M, Jafari A. Effect of L-carnitine supplementation in comparison with moderate aerobic training on serum inflammatory parameters in healthy obese women. J Sports Med Phys Fitness. 2015;55(11):1363-70.
27. Sahebkar A. Effect of L-carnitine supplementation on circulating C-reactive protein levels: A systematic review and meta-analysis. Journal of medical biochemistry. 2015;34(2):151.
28. Haghighatdoost F, Jabbari M, Hariri M. The effect of L-carnitine on inflammatory mediators: a systematic review and meta-analysis of randomized clinical trials. Eur J Clin Pharmacol. 2019;75(8):1037-46.
29. Harper P, Elwin C-E, Cederblad G. Pharmacokinetics of bolus intravenous and oral doses of L-carnitine in healthy subjects. European journal of clinical pharmacology. 1988;35(1):69-75.
30. Bain MA, Milne RW, Evans AM. Disposition and metabolite kinetics of oral l‐carnitine in humans. The Journal of Clinical Pharmacology. 2006;46(10):1163-70.
31. El-Sheikh AA, Rifaai RA. Peroxisome proliferator activator receptor (PPAR)-γ ligand, but not PPAR-α, ameliorates cyclophosphamide-induced oxidative stress and inflammation in rat liver. PPAR research. 2014;2014.
32. Chen K, Li J, Wang J, Xia Y, Dai W, Wang F, et al. 15-Deoxy-γ12, 14-prostaglandin J2 reduces liver impairment in a model of ConA-induced acute hepatic inflammation by activation of PPARγ and reduction in NF-κB activity. PPAR research. 2014;2014.
33. Chung K-P, Chen G-Y, Chuang T-Y, Huang Y-T, Chang H-T, Chen Y-F, et al. Increased plasma acetylcarnitine in sepsis is associated with multiple organ dysfunction and mortality: a multicenter cohort study. Critical care medicine. 2019;47(2):210-8.
34. Bonafé L, Berger MM, Que YA, Mechanick JI. Carnitine deficiency in chronic critical illness. Current Opinion in Clinical Nutrition & Metabolic Care. 2014;17(2):200-9.
35. Jones AE, Puskarich MA, Shapiro NI, Guirgis FW, Runyon M, Adams JY, et al. Effect of Levocarnitine vs Placebo as an Adjunctive Treatment for Septic Shock: The Rapid Administration of Carnitine in Sepsis (RACE) Randomized Clinical Trial. JAMA Netw Open. 2018;1(8):e186076.
36. Puskarich MA, Kline JA, Krabill V, Claremont H, Jones AE. Preliminary Safety and Efficacy of L‐carnitine Infusion for the Treatment of Vasopressor‐Dependent Septic Shock: A Randomized Control Trial. Journal of Parenteral and Enteral Nutrition. 2014;38(6):736-43.
37. Goetzman ES, Alcorn JF, Bharathi SS, Uppala R, McHugh KJ, Kosmider B, et al. Long-chain acyl-CoA dehydrogenase deficiency as a cause of pulmonary surfactant dysfunction. Journal of Biological Chemistry. 2014;289(15):10668-79.
38. Jennaro, T. S., M. A. Puskarich, et al. ”Using Lâ\euroCarnitine as a Pharmacologic Probe of the Interpatient and Metabolic Variability of Sepsis.” Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 40(9): 913-923.